Ownership and insider activity for Alzamend Neuro Inc (ALZN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a meth...
Price
| Price | $1.84 |
| Market Cap | $7M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-26 | AULT MILTON C III | S-Sale | 2,000 | $3K |
| 2026-04-14 | AULT MILTON C III | P-Purchase | 2,000 | $2K |
| 2026-07-31 | Hyperscale Data, Inc. | A-Award | 7,500 | |
| 2022-04-26 | Hyperscale Data, Inc. | 988 | $4.0M | |
| 2024-10-30 | Hyperscale Data, Inc. | 1,111 | $120K | |
| 2026-07-31 | AULT MILTON C III | A-Award | 7,500 | |
| 2026-04-17 | Nisser Henry Carl | A-Award | 60,000 | $140K |
| 2026-04-17 | AULT MILTON C III | A-Award | 100,000 | $233K |
| 2026-04-17 | Horne William B. | A-Award | 60,000 | $140K |
| 2026-04-17 | Oram Jeffrey | A-Award | 60,000 | $140K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4976 | $545000 | $42606 | $90285 | $1.9M | $14.1M | $5.1M | $376048 | $3.9M | $710689 |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | $424351 | $285354 | $194278 | $16210 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $57293 | $2.4M | $1.5M | $1.8M | $2.9M | $14.4M | $5.8M | $455242 | $4.2M | $1.8M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | $102909 | $79843 | $176346 | $425606 | $314866 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $132293 | $2.4M | $1.5M | $1.8M | $2.9M | $14.5M | $5.9M | $631588 | $4.6M | $2.1M |
| Accounts Payable | $125965 | $90088 | $1.1M | 0 | $503591 | $1.2M | $2.9M | $2.9M | $634761 | $1.3M |
| Short-term Debt | $591258 | 0 | $79 | 0 | $335303 | 0 | 0 | $300714 | 0 | 0 |
| Total Current Liabilities | $717223 | $96724 | $1.2M | $992306 | $899643 | $1.2M | $2.9M | $3.2M | $634761 | $1.3M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $717223 | $96724 | $1.2M | $992306 | $899643 | $1.2M | $2.9M | $3.2M | $634761 | $1.3M |
| Retained Earnings | -$1.6M | -$2.5M | -$7.4M | -$11.8M | -$16.8M | -$29.2M | -$44.1M | -$54.0M | -$58.5M | -$67.3M |
| Total Equity | -$584930 | $2.3M | $316915 | $821709 | $2.0M | $13.4M | $3.0M | -$2.6M | $4.0M | $733211 |
| Total Debt | $591258 | 0 | $79 | $63 | $335303 | 0 | 0 | $300714 | 0 | 0 |
| Net Debt | $586282 | -$545000 | -$42527 | -$90222 | -$1.6M | -$14.1M | -$5.1M | -$75334 | -$3.9M | -$710689 |
| Working Capital | -$659930 | $2.3M | $316915 | $821709 | $2.0M | $13.2M | $3.0M | -$2.8M | $3.5M | $418345 |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 1.31 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -57.29 |
Profitability
| Return on Equity | -277.71% |
| Return on Invested Capital | -1195.68% |
| Return on Assets | -421.88% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACXP · ADIL · APRE · BCDA · CDIO · CELZ · HCWB
Explore sector: Healthcare · Biotechnology
More sections of ALZN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks